Highbridge Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Highbridge Capital Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-33,189	Closed	-$1.1M	–	1497
2014 Q4	$1.1M	Buy	33,189 +6,246	+23%	+$203K	0.01%	621
2014 Q3	$790K	Buy	+26,943	New	+$894K	0.01%	734
2013 Q4	–	Sell	-13,185	Closed	-$356K	–	1212
2013 Q3	$356K	Buy	13,185 +4,126	+46%	+$116K	﹤0.01%	987
2013 Q2	$211K	Buy	+9,059	New	+$163K	﹤0.01%	1165

Other funds holding LGND

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Highbridge Capital Management's LGND Position: Q1 2015 in Review

Highbridge Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q1 2015, closing a stake of 33,189 shares — an estimated $1.1M sold.

Highbridge Capital Management first reported a position in LGND in Q2 2013 and held it in 4 quarters. The position peaked at $1.1M in Q4 2014. 187 funds tracked by Wall St. Rank hold LGND as of Q1 2015.

Highbridge Capital Management reported no remaining Ligand Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Highbridge Capital Management sold 33,189 Ligand Pharmaceuticals shares in Q1 2015, an estimated $1.1M.
Highbridge Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 4 quarters.
Highbridge Capital Management's Ligand Pharmaceuticals position peaked at $1.1M in Q4 2014.
187 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2015.

Based on Highbridge Capital Management's 13F filing for Q1 2015, filed 15 May 2015.